NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis $0.0003 0.00 (0.00%) As of 11/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Bio-Path Stock (NASDAQ:BPTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bio-Path alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.00▼$0.10Volume1 shsAverage Volume28,007 shsMarket Capitalization$16.17 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bio-Path Holdings, Inc. (NASDAQ: BPTH) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer and other serious diseases. The company uses its proprietary DNAbilize® technology, which is designed to package nucleic acids in lipid nanoparticles and deliver them to specific cells. Bio-Path’s lead product candidate is prexigebersen, also known as BP100.01, an antisense oligonucleotide designed to inhibit growth receptor-bound protein-2 (Grb-2), a protein involved in signaling pathways associated with cancer-cell survival and proliferation. The candidate has been studied in patients with acute myeloid leukemia and has also been evaluated in combination with chemotherapy for other hematologic malignancies. The company has developed additional product candidates directed at molecular targets involved in cancer, including STAT3. Bio-Path Holdings is headquartered in Houston, Texas, and its development activities have primarily focused on oncology treatments intended for use in the United States and other markets through clinical research and potential future commercialization. The company has been led by President and Chief Executive Officer Peter H. Nielsen, who has been associated with Bio-Path since its early development.AI Generated. May Contain Errors. Read More Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPTH Stock News HeadlinesBio-Path Holdings, Inc. Common Stock (BPTH)July 13, 2026 | nasdaq.comBio Path Holdings IncMay 16, 2026 | cnbc.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 13 at 1:00 AM | Porter & Company (Ad)Bio-Path Holdings Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comBio-Path Holdings Delays 10-Q FilingNovember 17, 2025 | tipranks.comBio-Path: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comBio-Path Holdings, Inc. (BPTH) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comBio-Path Holdings to Present at Life Sciences Virtual Investor ForumJune 9, 2025 | finance.yahoo.comSee More Headlines BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed this year? Bio-Path's stock was trading at $0.06 on January 1st, 2026. Since then, BPTH stock has decreased by 99.5% and is now trading at $0.0003. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($1.16) EPS for the quarter, topping analysts' consensus estimates of ($1.54) by $0.38. Read the conference call transcript. When did Bio-Path's stock split? Shares of Bio-Path reverse split before market open on Friday, February 23rd 2024.The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include Canopy Growth (CGC), NVIDIA (NVDA), Plug Power (PLUG), Tonix Pharmaceuticals (TNXP), Micron Technology (MU), NIO (NIO) and Aurora Cannabis (ACB). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BPTH CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,842.40% Return on Assets-337.48% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.00Miscellaneous Outstanding Shares53,901,000Free Float5,726,000Market Cap$16.17 thousand OptionableNo Data Beta-0.80 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BPTH) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Invisible Dollar ResetPorter Stansberry believes President Trump could be about to trigger the biggest change to America's money in ...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
